Evading Pgp activity in drug-resistant cancer cells: A structural and functional study of antitubulin furan metotica compounds

Molecular Cancer Therapeutics

Volumn 11, Issue 5, 2012, Pages 1103-1111

  Nguyen, Tam Luong ^a   Cera, Maria Rosaria ^c   Pinto, Andrea ^d   Lo Presti, Leonardo ^d   Hamel, Ernest ^b   Conti, Paola ^d   Gussio, Rick ^b   De Wulf, Peter ^c  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 (ETHYLTHIO)ETHYL 6 (FURAN 2 YL) 3 METHYL 4 OXO 4,5,6,7 TETRAHYDRO 1H INDOLE 2 CARBOXYLATE; ANTINEOPLASTIC AGENT; BETA TUBULIN; COLCHICINE; FURAN DERIVATIVE; GLYCOPROTEIN P; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER RESISTANCE; CHEMICAL ANALYSIS; CHIRALITY; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG BINDING SITE; DRUG CONFORMATION; DRUG PROTEIN BINDING; ENANTIOMER; FEMALE; HUMAN; HUMAN CELL; MALE; MICROTUBULE ASSEMBLY; MOLECULAR MODEL; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; FURANS; HUMANS; INDOLES; NEOPLASMS; P-GLYCOPROTEIN; STEREOISOMERISM; TUBULIN MODULATORS;

EID: 84862739117     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-11-1018     Document Type: Article

References (22)

1. Tobias JS, Hochhauser D, Souhami RL. Cancer and its management. 6th ed. Chichester, West Sussex, UK; Hoboken, NJ: Wiley-Blackwell; 2010.
2. Dumontet C, Jordan MA. Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov 2010;9:790-803.
3. Goda K, Bacso Z, Szabo G. Multidrug resistance through the spectacle of P-glycoprotein. Curr Cancer Drug Tar 2009;9:281-97.
4. Jackson JR, Patrick DR, Dar MM, Huang PS. Targeted anti-mitotic therapies: can we improve on tubulin agents? Nat Rev Cancer 2007;7:107-17. (Pubitemid 46160987)
5. Screpanti E, Santaguida S, Nguyen T, Silvestri R, Gussio R, Musacchio A, et al. A screen for kinetochore-microtubule interaction inhibitors identifies novel antitubulin compounds. PLoS One 2010;5:e11603.
6. Blessing RH. An empirical correction for absorption anisotropy. Acta Crystallogr A 1995;51:33-8.
7. Sheldrick GM. A short history of SHELX. Acta Crystallogr A 2008;64:112-22.
8. Available from: http://www.ccdc.cam.ac.uk/cgi-bin/catreq.cgi.
9. Kang GJ, Getahun Z, Muzaffar A, Brossi A, Hamel E. N-acetylcolchinol O-methyl ether and thiocolchicine, potent analogs of colchicine modified in the C ring. Evaluation of the mechanistic basis for their enhanced biological properties. J Biol Chem 1990;265:10255-9.
10. Biological Testing Branch. Bethesda, MD: National Cancer Institute. Available from: http://dtp.nci.nih.gov/branches/btb/ivclsp.html.
11. Hopert A, Uphoff CC, Wirth M, Hauser H, Drexler HG. Specificity and sensitivity of polymerase reaction (PCR) in comparison with other methods for the detection of mycoplasma contamination in cell lines. J Immunol Methods 1993;164:91-100.
12. Kellogg GE, Semus SF, Abraham DJ. Hint: a new method of empirical hydrophobic field calculation for CoMFA. J Comput Aid Mol Des 1991;5:545-52.
13. Ravelli RBG, Gigant B, Curmi PA, Jourdain I, Lachkar S, Sobel A, et al. Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. Nature 2004;428:198-202. (Pubitemid 38374318)
14. Nguyen TL, McGrath C, Hermone AR, Burnett JC, Zaharevitz DW, Day BW, et al.Acommon pharmacophore for a diverse set of colchicine site inhibitors using a structure-based approach. J Med Chem 2005;48:6107-16. (Pubitemid 41324618)
15. Ikai T, Yamamoto C, Kamigaito M, Okamoto Y. Immobilized polysaccharide-based chiral stationary phases for HPLC. Polym J 2006;38: 91-108.
16. Stringham RW. The use of polysaccharide phases in the separation of enantiomers. Adv Chromatogr 2006;44:257-90.
17. Ali I, Saleem K, Hussain I, Gaitonde VD, Aboul-Enein HY. Polysaccharides chiral stationary phases in liquid chromatography. Sep Purif Rev 2009;38:97-147.
18. Flack HD. On enantiomorph-polarity estimation. Acta Crystallogr A 1983;39:876-81.
19. Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 2006;6:813-23. (Pubitemid 44450469)
20. Alvarez M, Paull K, Monks A, Hose C, Lee JS, Weinstein J, et al. Generation of a drug-resistance profile by quantitation of mdr-1/P-glycoprotein in the cell-lines of the National-Cancer-Institute anticancer drug screen. J Clin Invest 1995;95:2205-14.
21. Munic V, Kelneric Z, Mikac L, Haber VE. Differences in assessment of macrolide interaction with human MDR1 (ABCB1, P-gp) using rhodamine-123 efflux, ATPase activity and cellular accumulation assays. Eur J Pharm Sci 2010;41:86-95.
22. Bai RL, Nguyen TL, Burnett JC, Atasoylu O, Munro MHG, Pettit GR, et al. Interactions of halichondrin B and eribulin with tubulin. J Chem Inf Model 2011;51:1393-404.